Daniel Dean
Physician Assistant · Boise, IDNPI 1114510062
Payments from drug & device makers
Across 123 payments — averaging $25.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$743
- Curonix LLC$660
- Medtronic$526
- Abbott$364
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$259
- Lilly USA, LLC$142
- plus $458 from 9 others
What the payments were for
- Travel & lodging$76324%
- Food & beverage$2,36175%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 42 | $743 |
| Curonix LLC | 10 | $660 |
| Medtronic | 9 | $526 |
| Abbott | 12 | $364 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $259 |
| Lilly USA, LLC | 8 | $142 |
| Upsher-smith Laboratories LLC | 6 | $118 |
| Pfizer | 4 | $73 |
| Amgen | 3 | $63 |
| Biodelivery Sciences International, Inc. | 3 | $53 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Vertex | 1 | $26 |
| Saluda Medical Americas, Inc. | 1 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,151 in reported general payments places this provider in the 85th percentile of 1,027 physician assistant providers in Idaho.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 21 | $55,379 |
| Oxymorphone Hcl ErOxymorphone Hcl | 15 | $19,803 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 660 | $18,769 |
| NucyntaTapentadol Hcl | 14 | $14,400 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 396 | $13,762 |
| Xtampza ErOxycodone Myristate | 21 | $10,350 |
| BelbucaBuprenorphine Hcl | 16 | $10,233 |
| MovantikNaloxegol Oxalate | 21 | $9,157 |
| Buprenorphine | 33 | $7,937 |
| Pregabalin | 153 | $6,859 |
| OxycontinOxycodone Hcl | 20 | $6,183 |
| Morphine Sulfate ErMorphine Sulfate | 256 | $6,140 |
| Oxycodone Hcl | 222 | $5,935 |
| Fentanyl | 36 | $5,383 |
| Naloxone Hcl | 52 | $3,576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $259 | $55,37921 claims |
| Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er, Belbuca | $19 | $34,98351 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,027 physician assistant providers in Idaho.
Other physician assistant in Boise
- Benjamin KernsBoise$100K
- Autumn HeumanBoise$28K
- Stuart ColdsnowBoise$8K
- Jeffrey SmithBoise$8K
- Stephanie RitariBoise$8K
- Michael LaneBoise$7K
- Daniel LeflerBoise$7K
- David KasamisBoise$6K
- Jessica SzwecBoise$6K
- Jaclyn GolusBoise$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.